Genzyme’s Ceredase
Executive Summary
NDA for recombinant glucocerebrosidase (r-GCR) for Gaucher disease has been filed, Genzyme announces May 20. The company has predicted that the recombinant form will improve supply. Placentally derived Ceredase is the only approved therapy for the indication.